Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totaling 22,107 shares, a growth of 575.0% from the May 31st total of 3,275 shares. Based on an average trading volume of 263,781 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baird Financial Group Inc. increased its position in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares during the last quarter. Rangeley Capital LLC boosted its holdings in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock worth $91,000 after buying an additional 75,024 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock valued at $100,000 after buying an additional 76,800 shares during the period. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Stock Down 2.6%

BRNS stock traded down $0.02 during mid-day trading on Friday, reaching $0.70. 6,869 shares of the company traded hands, compared to its average volume of 156,395. The firm’s 50 day moving average price is $0.67 and its 200 day moving average price is $0.66. The stock has a market cap of $28.59 million, a price-to-earnings ratio of -0.54 and a beta of -0.40. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.14.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.